Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. - Wikidata - awgldk - TriplyDB

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

http://www.wikidata.org/entity/Q33510317

about

Immunotherapy for metastatic renal cell carcinoma Targeted therapy for advanced renal cell carcinoma Contemporary Treatment of Metastatic Renal Cell Carcinoma Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinoma Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives Cytoreductive surgery in the era of targeted molecular therapy Current management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in review Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma Cytoreductive nephrectomy and its role in the present-day period of targeted therapy.Percutaneous biopsy for risk stratification of renal masses Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities Individualising treatment choices in a crowded treatment algorithm Circulating biomarkers in advanced renal cell carcinoma: clinical applications Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma Sunitinib in the treatment of metastatic renal cell carcinoma Medical treatment of renal cancer: new horizons Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study Immunotherapy for metastatic renal cell carcinoma.Renal cell carcinoma.Renal cell cancer: overview of the current therapeutic landscape.The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.Response to post-axitinib treatment in patients with metastatic renal cell carcinoma.Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group.Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients.Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2.Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

P2860

Q24186688-BF18EB58-5D32-44A8-B4B8-71EECBE3F58C Q24242946-869F5B16-1339-4C56-BAEC-526E4FC6CE55 Q26740594-BE88DA39-0185-4D9E-841A-4E5B98E73047 Q26747767-E40F8C7B-99F9-4EAA-A492-68618FF87A72 Q26751341-92BA063C-CD77-44A0-AAD1-173F743BA0AF Q26774134-1A7EDADA-B3C4-485B-BA90-5A64C3A4B8A7 Q26774515-7CF57E41-2FAB-4CFB-B6D6-959BD344756D Q26775769-F1D326E1-E896-419F-AE23-4D4B10FD1459 Q26783520-F6516F5E-0D08-4548-809E-88169980D7BE Q26783525-F7EA9C04-F00C-4862-AE28-1B98DED37D9B Q26852437-A014DD81-D97E-46B9-9465-B25D92D06302 Q27023669-21D96279-6CCF-4664-A1E9-EAEC02A1A626 Q27023770-E330A9D2-A882-4DB9-A0A0-AEFABC7C806D Q27852038-EF08F562-C2EC-47B0-BAC3-473A879CC775 Q28067482-5F4EF059-44AB-43D4-B18A-D029AD428E1F Q28072057-3584CD65-F61C-4FCF-8C3D-E38F5569BF96 Q28073174-DCAC7B30-209D-4AC5-85E3-5769321B552A Q28074834-8A7A0A5C-C262-4A03-9071-04DFF4BAEC25 Q28079861-C840C458-5DC2-42C9-9073-DDC4B67AF407 Q28545130-D1F801FB-780E-473A-ACA6-CC1681E696AC Q30234458-A3B6351D-2BA9-4D68-9591-A86AE14ACCC4 Q30235364-71E1925D-3FEE-4905-BA15-56148C0C6C58 Q30248354-FED33FE5-5C98-442A-847F-8C33E6045E81 Q30250343-F1CA5DF7-8088-461E-94EF-5EE612B6DC11 Q30277077-DA0CBB2E-7997-4044-9A90-355AAB72F4CA Q30382892-7C913CB2-7967-4696-87EF-F7BAC016D7C2 Q30472042-119C3B8D-DD18-4FDE-8944-08C1E029E30D Q30486440-0FF49FA2-E52A-49F2-AFF4-06CDA1492827 Q31102468-6D919A34-BB89-49A1-A272-A35B889EA5C7 Q31109447-AE96E9F2-73D8-476F-AD5B-8E7E8C4ED400 Q33396613-E5279AE2-B5E2-4BF5-998E-7D3C4BDBBE9F Q33396965-06662326-41D6-4AD3-9D4F-8AAE75EB5AA6 Q33399152-82B8EECA-DBFC-418E-9DF8-CBD694097CDC Q33408085-1189A0B8-CC3C-4DF3-9BDB-2AEEA32143F9 Q33417828-D70B8424-B120-4637-B9B6-8AF81C7B4B74 Q33422376-1E5E957A-BC46-4FBC-9AA6-2408CC75785C Q33423740-95B8518F-7C3E-46E6-AD43-C9AA04FF7E94 Q33424769-5AEB133B-8552-479C-AA88-254CB1C49E75 Q33426559-3A1CDF00-F162-4079-90AB-EEE278E89175 Q33426958-5D21D670-0BB6-48C5-9B28-E7D7A0914146

P2860

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

http://www.wikidata.org/entity/Q33510317

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Prognostic factors for overall ...... om a large, multicenter study.

@ast

Prognostic factors for overall ...... om a large, multicenter study.

@en

type

label

Prognostic factors for overall ...... om a large, multicenter study.

@ast

Prognostic factors for overall ...... om a large, multicenter study.

@en

prefLabel

Prognostic factors for overall ...... om a large, multicenter study.

@ast

Prognostic factors for overall ...... om a large, multicenter study.

@en

P1433

Q33510317-F9101EC1-0403-444A-8439-5E822803CBFE

P1476

Q33510317-F2E92BB3-6B4E-4C99-AF93-8C95F1C13C16

P2093

Q33510317-00E8588D-3A57-4B81-9E7D-77378BA43F8F

Q33510317-0F7D70A6-EEEF-4755-8FF6-87B0D4633B73

Q33510317-18D1C978-7DF6-4E3A-892D-928FCDB619D8

Q33510317-331CCF86-A29E-41BA-97D2-CBB50A3F7CF5

Q33510317-380A9EAB-B7B4-4D3C-98FC-84AB710FF5BD

Q33510317-3A5C37A3-5F3D-4E92-9643-772D00332D4F

Q33510317-3E609E47-0229-4BD2-89D0-C1E88DB1CBBD

Q33510317-6DEC4A76-7926-4B42-AF1D-AABC9BF1D041

Q33510317-6FBB3B4B-6AB8-4418-B9AE-AC7EA755EC34

Q33510317-7DDC62E0-13BB-4442-953B-EBF773FA3426

P304

Q33510317-ACD7F524-2084-4452-A41F-3A6618B103B7

P31

Q33510317-69F3F63D-4F05-4802-9333-BB08119891DD

P356

Q33510317-B0CFEC4D-EC11-4989-AB9D-F9233825577B

P407

Q33510317-F90AB014-87C3-40D2-8A6D-56D83A0EC5BE

P433

Q33510317-7FD642C4-4085-4113-A970-C705AA059601

P478

Q33510317-2745DF17-A21F-4CEA-9EC8-7D611A9BC53A

P50

Q33510317-0D671555-DA02-408D-8299-888BAE4E584E

P577

Q33510317-BB1DB8EA-855B-4108-A20A-66284881027C

P698

Q33510317-9830C49C-DE23-4A83-9A2D-1AB9C7AE57FD

P921

Q33510317-047C1191-9B5F-4AAF-8BBA-0EBDBE7A1B29

Q33510317-19E90411-8462-488B-A768-74665367CA7F

P356

JCO.2008.21.4809

P1433

Journal of Clinical Oncology

P1476

Prognostic factors for overall ...... om a large, multicenter study.

@en

P2093

Ali Reza Golshayan

http://www.w3.org/2001/XMLSchema#string

Bernhard J Eigl

http://www.w3.org/2001/XMLSchema#string

Brian I Rini

http://www.w3.org/2001/XMLSchema#string

Chakshu Sahi

http://www.w3.org/2001/XMLSchema#string

Christian Kollmannsberger

http://www.w3.org/2001/XMLSchema#string

Daniel Y C Heng

http://www.w3.org/2001/XMLSchema#string

David F McDermott

http://www.w3.org/2001/XMLSchema#string

J Dean Ruether

http://www.w3.org/2001/XMLSchema#string

Jennifer J Knox

http://www.w3.org/2001/XMLSchema#string

Kim N Chi

http://www.w3.org/2001/XMLSchema#string

P304

5794-5799

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.21.4809

http://www.w3.org/2001/XMLSchema#string

P407

P433

34

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-10-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19826129

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial